
About Genome & Company
Genome & Company is a publicly listed company based in Seongnam-si (South Korea) founded in 2015 by Jisoo Pae. Microbiome-based immuno-oncology drugs are developed using proprietary technology. The company has 102 employees. Genome & Company has completed 1 acquisition, including List Biological Laboratories. Its chief executive, as recorded, is Jisoo Pae. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics.
Company details
The company was founded in 2015 in Seongnam-si, South Korea, and operates in the biotechnology sector focused on microbiome therapeutics. Innovative drug candidates are developed through the GNOCLE platform, targeting immuno-oncology and other conditions. The pipeline includes GEN-001 and GEN-004 for cancer treatments, as well as SB-121 for autism and obstetric diseases. Leadership is provided by Co-Founder and CEO Jisoo Pae.
- Headquarters Seongnam-si, South Korea
- Employees 102
- Founders Jisoo Pae
- Stage Public
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Phoneβ’β’β’β’ β’β’β’β’
- Website genomecom.co.kr
- Legal Name Genome & Co.
- Annual Revenue$17.03 M (USD)-11.38as on Dec 31, 2025
- Net Profit-$4.45 M (USD)68.04as on Dec 31, 2025
- EBITDA-$15.62 M (USD)-27.25as on Dec 31, 2025
- Latest Funding Round$2.96M (USD), Post-IPO
Apr 2020
- InvestorsDongKoo Bio& Pharma
& 1 more
- Employee Count102
- Investments & Acquisitions
Funding Insights of Genome & Company
- Total Rounds 2
- Last Round Post-IPO β $2.96M
- Investors Count 2
All 2 funding rounds of Genome Company with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Apr 2020 | $2.96M | Post-IPO | β | β | |
| Jun 2016 | Seed | β | β |
2 investors in total: 2 institutional.
Investors in Genome & Company
Genome & Company has secured backing from 2 investors, including institutional and venture fund investors. Prominent investors backing the company include DongKoo Bio& Pharma and DSC Investment.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage venture capital is invested primarily in South Korean startups. | 2012 | dscinvestment.com | Seoul, South Korea | |
Company focused on generic medicines, OTC, stem cell extraction kits, medical apparatus, cosmetics & CMO services | 1970 | dongkoo.com | Seoul, South Korea |
Investor details for Genome Company
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Genome & Company
1 people are tracked at Genome & Company (1 in leadership); the tracked headcount is 102.
| Name | Role | Group |
|---|---|---|
Jisoo Pae | Co-Founder & CEO | Leadership |
Complete people profiles for Genome & Company
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Genome & Company
Genome & Company is a publicly listed company on the KRX with ticker symbol 314130 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date28 Dec 2018
- Listed onKRX: 314130
- Listed entityGenome & Co.
- Exchange sectorHealth technology
- ISINKR7314130006
- Share price4,750.00 KRW (-2.66% on the day) · 2026-10-14
- Market capitalisation255,221,203,918.00 KRW
- EPS (diluted, trailing year)-999.85 KRW
- Volume (last session)328,436
Financials of Genome & Company
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 24.59B KRW | -6.43B KRW | -22.56B KRW |
| 2024 | 27.74B KRW | -20.11B KRW | -17.73B KRW |
| 2023 | 14.30B KRW | -47.47B KRW | -47.98B KRW |
| 2022 | 14.08B KRW | -51.84B KRW | -48.63B KRW |
| 2021 | 451.2M KRW | -34.12B KRW | -34.76B KRW |
Detailed financial statements for Genome & Company
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Genome & Company
Genome & Company has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include List Biological Laboratories.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Specializes in the production of research reagents | listlabs.com | Campbell, United States | 1978 | Sep 2021 | $27M |
Complete acquisition details for Genome Company
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Genome & Company
5 dated milestones of Genome & Company across 6 years, from founding to its latest funding, stage changes and deals.
- Founded Genome & Company is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $3.0M.
- Acquisition Acquires List Biological Laboratories.
Web traffic of Genome & Company
The website of Genome & Company (genomecom.co.kr) receives about 4.3K visits a month.
- Monthly visits4.3K
▼ 9.6% vs previous month
Websites whose visitors overlap most with Genome & Company. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
yakup.com | yakup.com | 100% | #118,603 | β | |
dailypharm.com | dailypharm.com | 92% | #33,384 | β | |
| pharmnews.com | 92% | #274,610 | View details | ||
| hitnews.co.kr | 92% | #146,502 | View details | ||
| medicopharma.co.kr | 82% | #596,014 | View details |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Genome & Company
Complete news archive for Genome Company
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Genome & Company
Genome & Company was founded in 2015 and raised its 1st funding round 1 year after it was founded.
Genome & Company is headquartered in Seongnam-si, South Korea. It is registered at Seongnam-si, Gyeonggi-do, South Korea.
Jisoo Pae is the CEO of Genome & Company, as recorded in our data. They have also founded this company.
Genome & Company has 102 employees.
Annual revenue of Genome & Company is $17.03M as on Dec 31, 2025.
The company was founded in 2015 in Seongnam-si, South Korea, and operates in the biotechnology sector focused on microbiome therapeutics. Innovative drug candidates are developed through the GNOCLE platform, targeting immuno-oncology and other conditions. The pipeline includes GEN-001 and GEN-004 for cancer treatments, as well as SB-121 for autism and obstetric diseases. Leadership is provided by Co-Founder and CEO Jisoo Pae.
Yes, Genome & Company is publicly traded on KRX under the ticker symbol 314130.
Genome & Company has made 1 acquisition, including List Biological Laboratories.
Genome & Company has 2 investors. Key investors include DongKoo Bio& Pharma, and DSC Investment.
